Researchers developed a biomaterial releasing beneficial E. coli to combat urinary tract infections by outcompeting harmful bacteria, aiming to reduce antibiotic resistance and manage chronic UTIs ...
1. Current NAV: The Current Net Asset Value of the UTI Gilt Fund with 10 year Constant Duration - Direct Plan as of Nov 19, 2024 is Rs 12.03 for Growth option of its Direct plan. 2. Returns: Its ...
PHIOGEN, a biotech company developing live biotherapeutic products (LBPs) for drug-resistant and recurrent bacterial infections, is collaborating with patient research and advocacy organization Live ...